Literature DB >> 16094716

Implications of anti-parietal cell antibodies and anti-Helicobacter pylori antibodies in histological gastritis and patient outcome.

Ching-Chu Lo1, Ping-I Hsu, Gin-Ho Lo, Kwok-Hung Lai, Hui-Hwa Tseng, Chiun-Ku Lin, Hoi-Hung Chan, Wei-Lun Tsai, Wen-Chi Chen, Nan-Jing Peng.   

Abstract

AIM: To develop a serum or histological marker for early discovery of gastric atrophy or intestinal metaplasia.
METHODS: This study enrolled 44 patients with gastric adenocarcinoma, 52 patients with duodenal ulcer, 14 patients with gastric ulcer and 42 consecutive healthy adults as controls. Each patient received an endoscopy and five biopsy samples were obtained. The degrees of histological parameters of gastritis were categorized following the Updated Sydney System. Anti-parietal cell antibodies (APCA) and anti-Helicobacter pylori (H pylori) antibodies (AHPA) were analyzed by immunoassays. H pylori infection was diagnosed by rapid urease test and histological examination.
RESULTS: Patients with gastric cancer and gastric ulcer are significantly older than healthy subjects, while also displaying higher frequency of APCA than healthy controls. Patients with positive APCA showed higher scores in gastric atrophy and intestinal metaplasia of corpus than patients with negative APCA. Patients with positive AHPA had higher scores in gastric atrophy, intestinal metaplasia, and gastric inflammation of antrum than those patients with negative AHPA. Elderly patients had greater prevalence rates of APCA. Following multivariant logistic regression analysis, the only significant risk factor for antral atrophy is positive AHPA, while that for corpus atrophy is positive APCA.
CONCLUSION: The existence of positive APCA correlates with glandular atrophy in corpus and the presence of positive AHPA correlates with glandular atrophy in antrum. The existence of serum APCA and AHPA betokens glandular atrophy and requires further examination for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16094716      PMCID: PMC4615417          DOI: 10.3748/wjg.v11.i30.4715

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

Review 1.  Role of Helicobacter pylori in the pathogenesis of atrophic gastritis.

Authors:  E J Kuipers; E C Klinkenberg-Knol; C M Vandenbroucke-Grauls; B J Appelmelk; B E Schenk; S G Meuwissen
Journal:  Scand J Gastroenterol Suppl       Date:  1997

Review 2.  Cancer and infection: estimates of the attributable fraction in 1990.

Authors:  P Pisani; D M Parkin; N Muñoz; J Ferlay
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-06       Impact factor: 4.254

3.  Role of anti-parietal cell antibody in Helicobacter pylori-associated atrophic gastritis: evaluation in a country of high prevalence of atrophic gastritis.

Authors:  M Ito; K Haruma; S Kaya; T Kamada; S Kim; A Sasaki; M Sumii; S Tanaka; M Yoshihara; K Chayama
Journal:  Scand J Gastroenterol       Date:  2002-03       Impact factor: 2.423

4.  Most gastric cancer occurs on the distal side of the endoscopic atrophic border.

Authors:  T Yoshimura; T Shimoyama; S Fukuda; M Tanaka; A T Axon; A Munakata
Journal:  Scand J Gastroenterol       Date:  1999-11       Impact factor: 2.423

5.  Contribution of HLA-DQA gene to host's response against Helicobacter pylori.

Authors:  T Azuma; J Konishi; Y Tanaka; M Hirai; S Ito; T Kato; Y Kohli
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

Review 6.  Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994.

Authors:  M F Dixon; R M Genta; J H Yardley; P Correa
Journal:  Am J Surg Pathol       Date:  1996-10       Impact factor: 6.394

7.  Endoscopic 13C-urea breath test for the diagnosis of Helicobacter pylori infection.

Authors:  N J Peng; K H Lai; R S Liu; S C Lee; D G Tsay; C C Lo; H H Tseng; W K Huang; G H Lo; P I Hsu
Journal:  Dig Liver Dis       Date:  2003-02       Impact factor: 4.088

8.  Helicobacter pylori infection and chronic atrophic gastritis among Japanese blood donors: a cross-sectional study.

Authors:  A Fukao; S Komatsu; Y Tsubono; S Hisamichi; H Ohori; T Kizawa; N Ohsato; N Fujino; N Endo; M Iha
Journal:  Cancer Causes Control       Date:  1993-07       Impact factor: 2.506

9.  Gastric adenocarcinoma and Helicobacter pylori infection.

Authors:  N J Talley; A R Zinsmeister; A Weaver; E P DiMagno; H A Carpenter; G I Perez-Perez; M J Blaser
Journal:  J Natl Cancer Inst       Date:  1991-12-04       Impact factor: 13.506

10.  Serum pepsinogen I as a predictor of stomach cancer.

Authors:  A M Nomura; G N Stemmermann; I M Samloff
Journal:  Ann Intern Med       Date:  1980-10       Impact factor: 25.391

View more
  4 in total

1.  Indoleamine 2,3-Dioxygenase 1, Increased in Human Gastric Pre-Neoplasia, Promotes Inflammation and Metaplasia in Mice and Is Associated With Type II Hypersensitivity/Autoimmunity.

Authors:  Mohamad El-Zaatari; Adam J Bass; Reanne Bowlby; Min Zhang; Li-Jyun Syu; Yitian Yang; Helmut Grasberger; Andrew Shreiner; Bei Tan; Shrinivas Bishu; Wai K Leung; Andrea Todisco; Nobuhiko Kamada; Marilia Cascalho; Andrzej A Dlugosz; John Y Kao
Journal:  Gastroenterology       Date:  2017-09-11       Impact factor: 22.682

Review 2.  Chronic hypergastrinemia: causes and consequences.

Authors:  Lori A Orlando; Lane Lenard; Roy C Orlando
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

3.  Analysis of clinical characteristics of 2243 with positive anti-gastric parietal cell antibody.

Authors:  Yaping Guo; Yingxia Hao; Xiaoyan Li; Xin Liu; Ying Liang; Wenjie Song; Shuqin Guo
Journal:  J Clin Lab Anal       Date:  2020-02-28       Impact factor: 2.352

4.  Association between vitamin B12 level and anti-parietal cells and anti-intrinsic factor antibodies among adult Jordanian patients with Helicobacter pylori infection.

Authors:  Mahmoud H Ayesh; Khaled Jadalah; Eiman Al Awadi; Khaldoon Alawneh; Basheer Khassawneh
Journal:  Braz J Infect Dis       Date:  2013-06-06       Impact factor: 3.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.